BNTC - CIK 0001808898
The table below shows Benitec Biopharma Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | $75.00K | $73.00K | $59.00K | $102.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $18.33M | $15.61M | $12.77M | $11.27M | $7.02M | $3.00M |
| SG&A | $23.43M |
Benitec Biopharma Inc. reported annual revenue of $0.00 for fiscal year 2024. That is down 100.0% from $75.00K in fiscal 2023. Over the 6 fiscal years shown, annual revenue declined from $12.20M (FY 2019) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.99M |
| $6.38M |
| $6.65M |
| $6.51M |
| $5.57M |
| Operating income | -$41.77M | -$22.49M | -$19.08M | -$17.85M | -$13.60M | -$8.28M |
| Income tax | - | - | - | - | - | - |
| Net income | -$37.92M | -$21.75M | -$19.56M | -$18.21M | -$13.88M | -$8.27M |
| EPS (diluted) | -$1.05 | -$1.22 | -$14.12 | -$37.88 | -$3.23 | - |